Kamada to present Phase 2/3 clinical trial results of AAT to treat alpha-1 antitrypsin deficiency

May 15 2014

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.

Kamada management will host a conference call on Friday, May 16, 2014, at 8:30 a.m. Eastern time to discuss these results and to answer investor questions. Shareholders and other interested parties may participate in the call by dialing 844-825-0516 (domestic) or (809) 31-5362 (from Israel) or 315-625-3228 (international) and referencing conference ID number 47092646. The call will also be webcast live and archived on the Company's website at www.kamada.com.

A replay of the conference call will be accessible two hours after its completion through May 22, 2014, by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 47092646. The call will also be archived for 90 days on the Company's website at www.kamada.com.